First--generation human renal cell carcinoma xenografts in the Nb rat subrenal capsular assay model.
This laboratory has evaluated the subrenal capsular assay system previously in the Nb rat with the Nb rat prostate adenocarcinoma model. Human renal cell carcinoma xenografts are now being employed in our Nb rat SRC model, the advantage of this system being that one can determine the effect of chemotherapy in a very short period of time, i.e., 7 days. This method saves considerable time and expense and may serve as a useful indicator for effective chemotherapeutic agents in individual cancer patients. In our studies, cyclophosphamide was the only agent to produce a significant effect on tumor volume.
Drago
J R
JR
Department of Surgery, College of Medicine, Ohio State University, Columbus.
Smith
J J
JJ
D000818:Animals; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009368:Neoplasm Transplantation; D051381:Rats; D011919:Rats, Inbred Strains; D013370:Subrenal Capsule Assay; D014183:Transplantation, Heterologous
D003561:Cytarabine; D003520:Cyclophosphamide; D005472:Fluorouracil